Keran Sun

Dr. Keran Sun

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
KSKeran Sun
Keran Sun
KSKeran Sun
Keran Sun
XWXiuli Wang
Xiuli Wang
XCXiao-Bing Chen
Xiao-Bing Chen
We have previously discussed the pathological characteristics, clinical characteristics, detection methods, pathogenesis, and treatment of Epstein–Barr virus (EBV)-positive gastric cancer, but we have not discussed the unique immune microenvironment in EBV-positive gastric cancer. Here, we reviewed studies on the immune microenvironment in EBV-positive gastric cancer and found that CD8+ T lymphocytes and a small number of CD204+ macrophages infiltrate the immune microenvironment in EBV-positive gastric cancer. Moreover, immune checkpoints, such as IDO1 and PD-L1, are expressed at high levels in EBV-positive gastric cancer. Lastly, we also analyzed the mechanisms underlying the formation of the immune microenvironment in EBV-positive gastric cancer. Our findings and conclusions have significance in clinical guidance and provide research direction for basic experiments.

3 July 2025 in The Lancet Microbe
Verified
Journal Article
Open access
JNJingyuan Ning
Jingyuan Ning
KJKeqi Jia
Keqi Jia
MZMeng Zhang
Meng Zhang
JLJie Liu
Jie Liu
KSKeran Sun
Keran Sun

23 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
KSKeran Sun
Keran Sun
KJKeqi Jia
Keqi Jia
Background: The tumor microenvironment (TME) plays a critical role in cancer progression and treatment response. Stromal components, including cancer-associated fibroblasts (CAFs), extracellular matrix (ECM), and angiogenesis, contribute to tumor aggressiveness. However, a comprehensive stromal activity score integrating multiple stromal dimensions for pan-cancer prognosis prediction is lacking. Methods: We developed a Stromal Activity Score (SAS) integrating five stromal dimensions: CAF signature (12 genes), ECM remodeling (15 genes), TGF-β signaling (13 genes), angiogenesis (12 genes), and complement activation (11 genes). SAS was calculated using single-sample Gene Set Enrichment Analysis (ssGSEA) on TCGA pan-cancer data comprising 1,303 samples across 12 cancer types. Prognostic value was evaluated using Kaplan-Meier analysis and Cox regression. Immunotherapy response prediction was validated in two independent cohorts (IMvigor210, n=88; Liu2019, n=105). Results: Pan-cancer Cox regression demonstrated a significant association between SAS and overall survival (HR = 1.165, 95% CI: 1.065–1.275, P = 0.001). Per-cancer analysis identified BRCA (HR = 1.942, P = 0.022), STAD (HR = 1.684, P = 0.024), and LUSC (HR = 1.552, P = 0.038) as significant, though none survived FDR correction. SAS correlated strongly with ESTIMATE Stromal Score (Spearman ρ = 0.835) and moderately with Immune Score (ρ = 0.396). Immunotherapy validation showed consistent trends (IMvigor210: AUC = 0.602; Liu2019: AUC = 0.617). Time-dependent ROC analysis showed 1-year AUC = 0.596, 3-year = 0.579, 5-year = 0.559. Leave-one-out analysis identified angiogenesis removal as enhancing prognostic signal (HR = 3.737, P = 0.0002). Three distinct TME subtypes were identified with differential SAS profiles. Conclusions: SAS is a novel pan-cancer stromal activity score that captures TME biology with strong construct validity. Its clinical utility as a standalone biomarker remains modest, but it may complement existing immunotherapy biomarkers.

25 October 2025 in The Lancet Microbe
Verified
Journal Article
Open access
JNJingyuan Ning
Jingyuan Ning
KSKeran Sun
Keran Sun

27 August 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
KSKeran Sun
Keran Sun
HLHongru Li
Hongru Li
HCHao Chi
Hao Chi
YSYuxuan Song
Yuxuan Song
YNYun-Ze Niu
Yun-Ze Niu
HLHengrui Liu
Hengrui Liu
Immune checkpoint blockade has changed the management of several digestive system cancers, but its impact is highly context dependent. This review evaluates evidence for esophageal, gastric and gastroesophageal junction, colorectal, hepatocellular, biliary tract and gallbladder, and pancreatic cancers. Randomized phase III trials have established chemoimmunotherapy or dual-checkpoint strategies in advanced esophageal cancer, biomarker- and regimen-dependent first-line therapy in gastric cancer, PD-1-based therapy for MSI-H/dMMR colorectal cancer, atezolizumab–bevacizumab and STRIDE for unresectable hepatocellular carcinoma, and chemoimmunotherapy for advanced biliary tract cancer. Recent results also expand perioperative treatment: neoadjuvant checkpoint blockade produces high pathological response rates in dMMR colon cancer, adjuvant atezolizumab plus mFOLFOX6 improves disease-free survival in stage III dMMR colon cancer, and perioperative serplulimab improves event-free survival in PD-L1-positive resectable gastric cancer. These advances coexist with important negative findings. Pembrolizumab-containing therapy did not meet superiority end points in KEYNOTE-062, the initial adjuvant signal in IMbrave050 was not sustained, and unselected pancreatic ductal adenocarcinoma remains largely resistant to checkpoint blockade. Early vaccine, cellular, TIGIT, radiomics, spatial, and multi-omics studies remain hypothesis-generating and require external or randomized validation. Clinical interpretation should integrate evidence maturity, biomarker validity, immune-related toxicity, patient-reported outcomes, cost, access, and manufacturing demands rather than response rate alone.